Evaluation of efficacy of regimens containing zidovudine, stavudine and tinofovir
Abstract
Objective: Aim of the study , was to compare the efficacy of regimens containing zidovudine, stavudine and tinofovir by comparing CD4 counts of patients at the end of 2 years .We also aim to evaluate their efficacy, by comparing basal CD4 count and CD4 count at 2 years in patients on these three regimens.
Methodology: A retrospective observational study was conducted on 128 HIV patients, receiving various antiretroviral regimens in a teaching hospital in coastal Karnataka. Data of patients who were diagnosed to be HIV positive, receiving HAART and were attending the hospital for regular follow up once in six months was collected in data extraction form. Regimens containing zidovudine, stavudine and tinofovir were evaluated by comparing 2 year CD4s of patients. Effectiveness of each regimen was evaluated by comparing basal CD4 count with CD4 count at the end of 2 years.
Results: We did not find any significant difference in basal CD4 counts in 3 regimens. CD4 count at the end of 2 years differed significantly (P<0.05) between the groups. Stavudine receiving patients had significantly higher (P<0.05) CD4 count as compared to AZT treated patients. Patients treated with TDF had highly significant (P<0.0001) elevation in CD4 count compared to that of AZT. However d4T and TDF didn’t have significant difference in CD4 counts at the end of 2 years. Patients in each group had extremely significant elevation in CD4 counts (p=0.0000) as compared to basal levels.
Conclusion: We can conclude that TDF containing regimen is more effective than that containing AZT or d4T,based on the CD4 count at the end of 2 years and the extent of elevation of CD4 count.
Downloads
References
National AIDS Control Organization. Ministry of Health and Family Welfare, Government of India. 2009 August 26 [Last cited on 2010 Aug 31]. Available from: https://nacoonline.org/NACO.
Bender MA, Kumarasamy N, Mayer KH, Wang B, Walensky RP, Flanigan T, Schackman BR, Scott CA, Lu Z, Freedberg KA. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis. 2010 Feb 1;50(3):416-25. doi: https://doi.org/10.1086/649884.
World Health Organization (2006) Antiretroviral therapy for HIV infecction inadults and adolescents in resource-limited settings: towards universal access.
World Health Organization (2010) Antiretroviral therapy for HIV infection inadults and adolescents: recommendations for a public health approach, 2010revision.https://www.who.int/hiv/pub/arv/adult2010/en/.
World Health Organization (2007) Addendum to 2006 WHO Guidelines onantiretroviral therapy for HIV infection in adults and adolescents.
Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba CB, et al.Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune DeficSyndr 2010; 54(1): 63–70. doi: https://doi.org/10.1097/QAI.0b013e3181c6c65c
Bygrave H, Ford N, van Cutsem G, Hilderbrand K, Jouquet G, Goemaere E, Vlahakis N, Triviño L, Makakole L, Kranzer K. Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years. J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):e75-8. doi: https://doi.org/10.1097/QAI.0b013e3182097505.
Velen K, Lewis JJ, Charalambous S, Grant AD, Churchyard GJ, Hoffmann CJ. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. PLoS One. 2013 May 14;8(5):e64459. doi: https://dx.doi.org/10.1371%2Fjournal.pone.0064459. Print 2013.
Umapathy S, ArunaP, Amar P and Kanjaksha G .CD4 count and viral load response to different anti retroviraltreatment regimen among AIDS patients from Mumbai, Western India. Retrovirology2009, 6(Suppl 2):P81.doi: https://dx.doi.org/10.1186%2F1742-4690-6-S2-P81.
VéroniqueJ, Philippe F, Vincent M, Françoise BV, Gastaut JA, Cecile G et al..Efficacy of Zidovudine Compared to Stavudine, Both in Combination with Lamivudine and Indinavir, in Human Immunodeficiency Virus-Infected Nucleoside-Experienced Patients with No Prior Exposure to Lamivudine, Stavudine, or Protease Inhibitors (Novavir Trial). Antimicrobial agents and chemotherapy 2002;6(18) : 1906–1913.doi : https://doi.org/10.1128/AAC.46.6.1906-1913.2002.
Karelia BN,Buch GJ.Treatment outcome of patients with HIV and TB.IJRPP 2012;1(2):151-158.
Osler M S, Stead D, Rebe KMeintjes G and Boulle et al. Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-controlstudy. HIV Medicine 2010;11(2):121-129.doi: https://doi.org/10.1111/j.1468-1293.2009.00754.x.
Laurent C, Bourgeois A, Mpoudi-Ngolé E, Ciaffi L, Kouanfack C, Mougnutou R, Nkoué N, Calmy A, Koulla-Shiro S, Delaporte E. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon. AIDS Res Hum Retroviruses. 2008 Mar;24(3):393-9. doi: https://doi.org/10.1089/aid.2007.0219.
Bae WH, Wester C, Smeaton LM, Shapiro RL, Lockman S, Onyait K, Thior I, Essex M. Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. AIDS. 2008 Aug 20;22(13):1633-40. doi: https://dx.doi.org/10.1097%2FQAD.0b013e328307a029.
Curkendall SM, Richardson JT, Emons MF, Fisher AE, Everhard F. Incidence ofanaemia among HIV-infected patients treated with highly active antiretroviraltherapy. HIV Medicine 2007;8(8):483-90.doi: https://doi.org/10.1111/j.1468-1293.2007.00500.x
Swapnil CJ, Jyoti RP, Vijay MotiramMotghare,SudhirLaxmanraoPadwal et al. A prospective study, to determine adverse effects of anti-retroviralagents in rural tertiary care teaching hospital. Int J Basic ClinPharmacol. 2016 Jun;5(3):713-717.doi: http://dx.doi.org/10.18203/2319-2003.ijbcp20161506.
Emnet KM, Lukman M, Muhammad NM, Marianti AM. Effectiveness of Tenofovir (TDF) / Emtricitabine (FTC) Versus Zidovudine (AZT) / Lamivudine (3TC) in Combination with Efavirenz (EFV) IN Antiretroviral-Naive HIV-Infected Patients IN Eritrea International Journal of Pharmaceutical and Clinical Research 2015; 7(5): 364-67. http://impactfactor.org/PDF/IJPCR/7/IJPCR,Vol7,Issue5,Article9.pdf.
Bender MA, Kumarasamy N, Mayer KH, Wang B, Walensky RP, Flanigan T, Schackman BR, Scott CA, Lu Z, Freedberg KA. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis. 2010 Feb 1;50(3):416-25. doi: https://doi.org/10.1086/649884.
Jouquet G, Bygrave H, Kranzer K, Ford N, Gadot L, Lee J, Hilderbrand K, Goemaere E, Vlahakis N, Trivino L, Makakole L, Cleary S. Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho. J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):e68-74. doi: https://doi.org/10.1097/QAI.0b013e31822a9f8d.
Bendavid E, Grant P, Talbot A, Owens DK, Zolopa A .Cost-effectiveness of antiretroviral regimens in the World Health Organization’s treatment guidelines: a South African analysis. AIDS 2011; 25((2): 211–20. doi: https://doi.org/10.1097/qad.0b013e328340fdf8.
Alana TB, Mhairi M, Prudence I, Kate S, Lawrence L, Ian S et al ,. Increases in regimen durability associated with the introductionof tenofovir at a large public-sector clinic in Johannesburg,South Africa .Journal of the International AIDS Society 2013; 16(1):18794.doi: https://doi.org/10.7448/IAS.16.1.18794.
Campaign for Access to Essential Medicines. 2008. Untangling the Webof Antiretroviral Price Reductions, 11th ed. Geneva: Me´decins sans Frontie` res. Available from: http://d2pd3b5abq75bb.cloudfront.net/2012/07/16/14/49/04/691/UTW_11_ENG_Jul2008.pdf.
World Health Organization. Consolidated guidelines on the use ofantiretroviral drugs for treating and preventing HIV infection: recommendationsfor a public health approach. Geneva: World Health Organization; 2013.https://www.who.int/hiv/pub/arv/arv-2016/en/.
Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, Shlipak MG. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012 Apr 24;26(7):867-75. doi: https://doi.org/10.1097/QAD.0b013e328351f68f.
von Wyl V, Cambiano V, Jordan MR, Bertagnolio S, Miners A, Pillay D, Lundgren J, Phillips AN. Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. PLoS One. 2012;7(8):e42834. doi: https://dx.doi.org/10.1371%2Fjournal.pone.0042834. Epub 2012 Aug 8.
OAI - Open Archives Initiative
